Clinical trial
Intermediate-Size Expanded Access Protocol (EAP) for LP352
NCT06149663
Study timeline
Registry last updated2025-01-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Interventions
LP352DRUG
Sponsors & collaborators
Longboard Pharmaceuticalslead sponsor
Mapped research locations
New YorkNew York, United States2ChicagoIllinois, United States1Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1St LouisMissouri, United States1San FranciscoCalifornia, United States1ClevelandOhio, United States1TampaFlorida, United States1PortlandOregon, United States1OrlandoFlorida, United States1AuroraColorado, United States1AustinTexas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06149663 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.